Similar Infection Risk for Two MS Antibody Treatments

Credibility

Interest

Share:2 min read

Key Takeaway

Two common MS antibody treatments, rituximab and ocrelizumab, carry similar infection risk but both lower relapse risk compared with other MS drugs.

What They Found

Researchers looked at almost 17,000 treatment periods in Sweden to compare infections and relapses with different MS medicines. They focused on two similar drugs, rituximab and ocrelizumab, which both target a type of immune cell (called B cells) that can be overactive in MS; think of these drugs like a dimmer switch for part of the immune system. Both of these drugs had higher rates of infections compared with other MS drug types, meaning people on them had more infections reported or needed antibiotics more often. At the same time, both drugs showed much lower relapse rates, so they were effective at preventing MS flare-ups. Importantly, the study found no meaningful difference in infection or relapse risk between rituximab and ocrelizumab — they performed similarly in this large real-world group.

Who Should Care and Why

People with MS and their caregivers should know that choosing rituximab or ocrelizumab may mean fewer relapses but a somewhat higher chance of infections, so watching for signs of infection is important. Healthcare providers should use this information when discussing trade-offs: think of it as balancing stronger relapse protection against a greater need to be alert for infections. Those who are more likely to get infections (for example, older adults or people with other health problems) might want extra discussion with their doctor about monitoring and prevention, like vaccines or infection checks. Caregivers can help by reminding patients about hand washing, avoiding sick contacts, and reporting fevers or coughs quickly — small actions that reduce infection risk, like using an umbrella when it rains. Overall, anyone deciding between these drugs can expect similar infection and relapse outcomes, so personal health, preferences, and practical supports often guide the final choice.

Important Considerations

This study looked at real-world medical records, which shows how these drugs work in everyday practice, but it can’t prove cause and effect like a randomized trial would. The findings are based on Swedish healthcare data and may not match every country or patient group, so talk with your MS team about how this applies to you. The study did not capture every possible side effect or individual differences, so personal medical history and monitoring plans still matter a lot.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Clinical Trials Treatment Updates MS Progression

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News